GLUE NASDAQ
Monte Rosa Therapeutics, Inc.
1W: -6.2%
1M: -9.0%
3M: -50.6%
YTD: -30.4%
1Y: -4.3%
3Y: +289.1%
5Y: -52.8%
$10.66
+0.18 (+1.72%)
Pre-Market: $11.16 (+0.50, +4.74%)
Weekly Expected Move ±9.1%
$9
$10
$11
$12
$13
Credit Risk of going bust: higher than 56% of companies Debt: 4.0% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.08 (down 99.3%), Monte Rosa Therapeutics, Inc. would be worth roughly what it owes.
Total debt $38.0M against a stock market value of $909.4M.
Distance to default 4.57 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $21.3M (short-term plus half of long-term), stock volatility 78.8%; Altman Z'' 3.56. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.08 (down 99.3%), Monte Rosa Therapeutics, Inc. would be worth roughly what it owes.
Total debt $38.0M against a stock market value of $909.4M.
Distance to default 4.57 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $21.3M (short-term plus half of long-term), stock volatility 78.8%; Altman Z'' 3.56. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
6 relationships6
As Filer
counterparties named
0
As Counterparty
mentioned by others
1
Rel. Types
2023-10-17
Earliest Filing
2026-01-09
Latest Filing
partner: 6
Counterparties (Filed by GLUE)
6 relationshipsCompanies named in GLUE's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Jefferies LLC | JEF | partner | Underwriter for the public offering of common stock and pre-funded warrants | 2026-01-09 | View |
| Piper Sandler & Co. | PIPR | partner | Underwriter for the public offering of common stock and pre-funded warrants | 2026-01-09 | View |
| Novartis Pharma AG | NVSEF | partner | Entered into a Collaboration, Option, and License Agreement for the discovery and development of degraders to treat immu | 2025-09-15 | View |
| Novartis Pharma AG | NVSEF | partner | Entered into a global exclusive license agreement with Monte Rosa Therapeutics to develop and commercialize VAV1 molecul | 2024-10-28 | View |
| F. Hoffmann-La Roche Ltd | — | partner | Entered into a Collaboration and License Agreement with Monte Rosa Therapeutics to develop molecular glue degraders. | 2023-10-17 | View |
| Hoffmann-La Roche Inc | — | partner | Jointly entered into a Collaboration and License Agreement with Monte Rosa Therapeutics to develop molecular glue degrad | 2023-10-17 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-10-01 | Regulation FD; Other Events; Exhibits | View | |
| 2026-09-08 | Regulation FD; Other Events; Exhibits | View | |
| 2026-08-06 | Earnings Release; Exhibits | View | |
| 2026-06-11 | Shareholder Vote | View | |
| 2026-05-07 | Earnings Release; Exhibits | View | |
| 2026-03-17 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-02-10 | Departure/Election of Directors; Appointment of Officers | View | |
| 2026-01-09 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
| 2026-01-07 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2026-01-07 | Other Events; Financial Statements and Exhibits | View | |
| 2025-12-16 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-11-06 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-09-15 | Entry into Material Definitive Agreement; Regulation FD Disclosure; Financial Statements and Exhibit | Agreement | View |
| 2025-08-07 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-06-13 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-05-08 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-03-20 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-01-10 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2024-12-13 | Departure/Election of Directors; Appointment of Officers | View | |
| 2024-12-05 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR